A PHASE 1 SAFETY AND PHARMACOKINETIC STUDY OF SU011248 AND CAPECITABINE IN PA

SU011248 和卡培他滨在 PA 中的 1 期安全性和药代动力学研究

• 批准号: 7379149
• 负责人: CHRISTOPHER J SWEENEY
• 金额: $ 0.02万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379149
• 关键词: PHASE; SAFETY; PHARMACOKINETIC; STUDY; SU011248

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Receptor tyrosine kinases (RTKs) are transmembrane proteins containing extracellular ligand-binding domains and intracellular catalytic domains. RTKs are activated following binding of their cognate ligands and many of the processes involved in tumor growth, progression and metastases are mediated by signaling molecules acting downstream from these proteins [1, 2]. Several members of the split-kinase domain family of RTKs are implicated in deregulated/autocrine proliferation and survival of solid and hematologic cancer cells. These include the platelet-derived growth factor receptors (PDGFR and ); vascular endothelial growth factor receptors (VEGFR) Type 1 and 2 (FLT1 and FLK 1/KDR); the stem cell factor (SCF) receptor, KIT; and the FLT3-ligand receptor. In addition RTKs PDGFR and VEGFR are implicated in tumor-dependent angiogenesis. SU011248 is a small molecule with the molecular formula C22H27FN4O2. The free base has a molecular weight of 398.48 and the L-malate salt, the form used in clinical trials (Error! Reference source not found.), has a molecular weight of 532.57. The chemical name of the L-malate salt is 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethylpyrrole-3-carbo ylic acid (2-diethylamino-ethyl)-amide, compound with (S)-2-hydroxy-succinic acid 1:1.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。受体酪氨酸激酶(RTK)是由胞外配体结合区和胞内催化区组成的跨膜蛋白。RTK在它们的同源配体结合后被激活，许多参与肿瘤生长、进展和转移的过程是由这些蛋白下游的信号分子介导的[1，2]。RTK分裂蛋白结构域家族中的几个成员与实体和血液肿瘤细胞的去调节/自分泌增殖和生存有关。这些受体包括血小板衍生生长因子受体(PDGFR和)；血管内皮生长因子受体(VEGFR)1型和2型(Flt1和Flk1/KDR)；干细胞因子(SCF)受体试剂盒；以及Flt3配体受体。此外，RTKs、PDGFR和VEGFR参与肿瘤依赖性血管生成。SU011248是分子式为C22H27FN4O2的小分子。游离碱的相对分子质量为398.48，L-苹果酸盐是临床试验中使用的形式(错误！未找到参考源。)，其分子量为532.57。L-苹果酸盐的化学名称为5-(5-fluoro-2-oxo-1，2-dihydro-indol-3-ylidenemethyl)-2，4-dimethylpyrrole-3-carbo-丙酸(2-二乙氨基乙基)-酰胺，与(S)-2-羟基-丁二酸的化合物为1：1。